MedTrace Logo

Shortening Duration of Antiarrhythmic Medication for SVT in Infants

NCT04837261 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2025-11-20

No results posted yet for this study

Summary

The infants diagnosed with SVT are treated with antiarrhythmic medication to prevent the recurrence of SVT. This prospective observational cohort study evaluates efficacy and safety of shortening duration of antiarrhythmic medication to four months in infants with SVT. Primary outcome is incidence of recurrent SVT in infants after 4 months of antiarrhythmic medication compared to retrospectively reviewed cohort.

Conditions

  • Supraventricular Tachycardia

Interventions

DRUG

Propranolol

3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months

DRUG

Flecainide

80 mg/m2/d

DRUG

Amiodarone

Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d

Sponsors & Collaborators

  • Helsinki University Central Hospital

    collaborator OTHER

  • Kuopio University Hospital

    collaborator OTHER

  • Oulu University Hospital

    collaborator OTHER

  • Turku University Hospital

    collaborator OTHER_GOV

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Tuija Poutanen, MD · Tampere University Hospital

Eligibility

Max Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04837261 on ClinicalTrials.gov